-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: federal funding
Raising the Stakes in Biotech
Small biotech companies continue to struggle to obtain funding as capital markets remain tight. The S&P downgrade may create even tighter credit markets and raise the cost of available credit, for small and large companies. To the extent that the downgrade leads capital flows out of the U.S., that hurts biotech. Biotech’s contributions to the world are critically needed. Our industry holds great promise for curing and treating many prevalent diseases, such as Alzheimer’s, cancer, Read More >
Bayh Dole Act a failure?
By Guest Writer Joseph Allen One hotly debated topic in Washington of real importance to the biotechnology community is how well the annual multi-billion dollar federal investment in R&D is being translated into new products, jobs and companies needed to improve the lives of US taxpayers and help pull the US economy out of its current doldrums. An interesting insight on the debate is captured in a Washington Post article “Innovation’s golden opportunity” that ran Read More >
